Keytruda/Lenvima combo shows promise in hard-to-treat cancers
The Pharma Data
SEPTEMBER 21, 2020
“These new data from our LEAP clinical program show encouraging activity across several aggressive cancer types and expand our knowledge about the potential of KEYTRUDA plus LENVIMA to help a range of patients with these cancers,” said Scot Ebbinghaus, vice president, Clinical Research, Merck Research Laboratories.
Let's personalize your content